Treatment of raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5‐HT2) receptor
Tóm tắt
Ketanserin, a selective antagonist of the 5‐HT2 receptor, was evaluated in a 4‐week open pilot trial of 30 patients with Raynaud's phenomenon. Moderate or marked relief was reported in 15 of 18 (83%) patients with systemic sclerosis, whereas only 4 of 12 (33%) patients with Raynaud's phenomenon of other etiology received such benefit (
Từ khóa
Tài liệu tham khảo
LeRoy EC, 1981, Scleroderma (systemic sclerosis), Textbook of Rheumatology, 1211
Rodnan GP, 1979, Progressive systemic sclerosis (scleroderma), Arthritis and Allied Conditions, 762
Van Nueten JM, 1981, Vascular effects of ketanserin (R 41,468), a novel antagonist of 5‐HT2 serotonergic receptors, J Pharmacol Exp Ther, 218, 217
Ensink FBM, 1981, The reliability of venous capacity and blood flow determination by plethysmography (JSI‐Periflow) III. Methodical considerations, Noninvasive Methods on Cardiovascular Hemodynamics, 201
Brugmans J, 1981, Venous occlusion plethysmography in the assessment of peripheral vascular changes, Noninvasive Methods on Cardiovascular Hemodynamics, 485
Investigational New Drug Brochure, 1982, Ketanserin: the first pure and selective 5‐HT2‐receptor blocking agent, 102
Maricq HR, 1982, Early detection of scleroderma‐spectrum disorders by in vivo capillary microscopy, J Rheumatol, 9, 289
Alexander EL, 1981, Scleroderma heart disease: evidence for cold‐induced abnormalities of myocardial function and perfusion (abstract), Arthritis Rheum (suppl), 24, S58
Brown H, 1977, Serotonin‐producing tumors, Serotonin in Health and Disease, 393
Stachow A, 1979, Biogenic amines derived from tryptophan in systemic and cutaneous scleroderma, Acta Dermatovener, 59, 1